Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harvard Apparatus Regenerative Technology, Inc.BSTG · Entity 7501 | Director | March 14, 2018 | March 28, 2018 |
| ImmunoGen, Inc.IMGN · Entity 94428 | EVP & Chief Business Officer | July 01, 2019 | July 02, 2019 |
| VBI Vaccines Inc/BCVBIV · Entity 111039 | Director | July 27, 2023 | July 28, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harvard Apparatus Regenerative Technology, Inc.
Report date March 14, 2018 · Filed March 28, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 912 |
Reported balance
After 2018-03-14 transaction · row 1
1 source rowRow 1 · 2018-03-14 · Exercise / conversion · Acquired 912 · Balance 912 F1: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2018-03-14 | Direct | 0 |
Reported balance
After 2018-03-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2018-03-14 · Exercise / conversion · Disposed 912 · Balance 0 F1: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock.
ImmunoGen, Inc.
Report date July 01, 2019 · Filed July 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 5,230 |
Reported balance
After 2019-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2019-07-01 · Grant · Acquired 5,230 · Balance 5,230 F1: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from January 1, 2019 through June 30, 2019. F2: In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from January 1, 2019 through June 30, 2019.
F2: In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2019.
VBI Vaccines Inc/BC
Report date July 27, 2023 · Filed July 28, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option (Right to Buy Common Shares)SEC Table II · derivative / convertible security · Conversion / exercise price $1.30 · Expires 2033-07-27 | Direct | 35,000 |
Reported balance
After 2023-07-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-07-27 · Grant · Acquired 35,000 · Balance 35,000 F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on July 27, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 27, 2023 (the "Option Agreement"). The options vest and become exercisable in 12 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on July 27, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 27, 2023 (the "Option Agreement"). The options vest and become exercisable in 12 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date.
F2: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2023 Filed Jul 28, 2023 18:30 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 35,000 | $0.00 Strike: $1.30 | $0.00 |
DisclosureSEC source: 0001493152-23-025951 · ownership.xml · derivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Shares · 35,000 shares Expires 2033-07-27 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on July 27, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated July 27, 2023 (the "Option Agreement"). The options vest and become exercisable in 12 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| January 26, 2023 Filed Jan 30, 2023 17:00 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 50,000 | $0.00 Strike: $0.58 | $0.00 |
DisclosureSEC source: 0001493152-23-002971 · ownership.xml · derivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Shares · 50,000 shares Expires 2033-01-26 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 26, 2023 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 26, 2023 (the "Option Agreement"). The options vest and become exercisable in 12 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| January 27, 2022 Filed Jan 31, 2022 17:57 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 75,000 | $0.00 Strike: $1.53 | $0.00 |
DisclosureSEC source: 0001493152-22-002788 · ownership.xml · derivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2032-01-27 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 27, 2022 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 27, 2022 (the "Option Agreement"). The options vest and become exercisable in 12 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| January 27, 2021 Filed Jan 29, 2021 18:21 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 75,000 | $0.00 Strike: $3.15 | $0.00 |
DisclosureSEC source: 0001493152-21-002153 · ownership.xml · derivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2031-01-27 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 27, 2021 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 27, 2021 (the "Option Agreement"). The options vest and become exercisable in 12 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| January 22, 2020 Filed Jan 24, 2020 17:26 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 250,000 | $0.00 Strike: $1.46 | $0.00 |
DisclosureSEC source: 0001493152-20-001089 · ownership.xml · derivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2030-01-22 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 22, 2020 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 22, 2020 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| July 01, 2019 Filed Jul 2, 2019 13:38 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantCommon Stock | 5,230 | $1.84 | $9,623.20 |
DisclosureSEC source: 0001179110-19-008313 · edgar.xml · nonDerivative · entry 1 McKee Blaine H. · CIK 0001669133 · EVP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,230 F1 · security: These shares were purchased due to participation by the reporting individual in the ImmunoGen Employee Stock Purchase Plan ("ESPP"). It pertains to the ESPP purchase period from January 1, 2019 through June 30, 2019. F2 · price: In accordance with the ESPP; these shares were purchased based on 85% of the closing price of the issuer's common stock on June 30, 2019. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 17:21 UTC | VBI Vaccines Inc/BC VBIV · Entity 111039 | GrantOption (Right to Buy Common Shares) · Derivative | 300,000 | $0.00 Strike: $1.67 | $0.00 |
DisclosureSEC source: 0001493152-19-001346 · ownership.xml · derivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Shares · 300,000 shares Expires 2029-01-31 F1 · derivative.exercise_date: The reporting person is a participant in the Issuer's Incentive Plan (the "Plan"). The board of directors of the Issuer approved the option grant on January 31, 2019 (the "Grant Date"). The options were granted pursuant to that certain option agreement entered into by and between the Issuer and the reporting person, dated January 31, 2019 (the "Option Agreement"). The options vest and become exercisable in 36 equal monthly installments beginning on the first day of the month following the Grant Date, subject to the reporting person's employment on the relevant vesting date. F2 · derivative.expiration_date: The options expire 10 years from the Grant Date unless terminated sooner in accordance with the Plan or the Option Agreement. Read SEC document |
| January 31, 2019 Filed Feb 4, 2019 16:35 UTC | ImmunoGen, Inc. IMGN · Entity 94428 | GrantStock Option (right to buy) · Derivative | 173,140 | $5.25 Strike: $5.25 | $908,985.00 |
DisclosureSEC source: 0001179110-19-001227 · edgar.xml · derivative · entry 1 McKee Blaine H. · CIK 0001669133 · EVP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,140 Underlying: Common Stock · 173,140 shares Expires 2029-01-31 F1 · derivative.exercise_date: Exercisable in three equal installments over three years starting on the first year anniversary of the grant. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 17:14 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | Exercise / conversionRestricted Stock Units · Derivative | 912 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001144204-18-017605 · tv489777_form4.xml · derivative · entry 2 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 912 shares Expires 2018-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2018 Filed Mar 28, 2018 17:14 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | Exercise / conversionCommon Stock | 912 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001144204-18-017605 · tv489777_form4.xml · nonDerivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 912 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit was the economic equivalent of one share of the Issuer's common stock. The reporting person settled the vested restricted stock units for shares of the Issuer's common stock. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:16 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantRestricted Stock Units · Derivative | 18,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-015091 · v461952_4.xml · derivative · entry 2 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,250 Underlying: Common Stock, par value $0.01 per share · 18,250 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units granted by the Issuer pursuant to its 2013 Equity Incentive Plan and qualified under Rule 16b-3(d). Each restricted stock unit represents a contingent right to receive one share of Common Stock of the Issuer. F3 · derivative.exercise_date: The restricted stock units vest and settle in full one year from the date of grant. F3 · derivative.expiration_date: The restricted stock units vest and settle in full one year from the date of grant. Read SEC document |
| March 14, 2017 Filed Mar 16, 2017 16:16 UTC | Harvard Apparatus Regenerative Technology, Inc. BSTG · Entity 7501 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.38 | $0.00 |
DisclosureSEC source: 0001144204-17-015091 · v461952_4.xml · derivative · entry 1 McKee Blaine H. · CIK 0001669133 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock, par value $0.01 per share · 25,000 shares Expires 2027-03-14 F1 · derivative.exercise_date: The option shares vest in full one year from the date of grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.